OM
ENTA icon

Opaleye Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Opaleye Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58M Buy
125,000
+50,000
+67% +$670K 0.21% 47
2025
Q4 		$1.18M Buy
+75,000
New +$953K 0.16% 49
2017
Q4 		– Sell
-100,000
Closed -$4.68M – 37
2017
Q3 		$4.68M Hold
100,000
– – 1.66% 21
2017
Q2 		$3.6M Hold
100,000
– – 1.5% 20
2017
Q1 		$3.08M Buy
100,000
+10,000
+11% +$311K 1.53% 22
2016
Q4 		$3.02M Buy
+90,000
New +$2.58M 1.78% 21

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Opaleye Management's ENTA Position: Q1 2026 in Review

Opaleye Management increased its Enanta Pharmaceuticals (ENTA) stake by 67% in Q1 2026, buying an estimated $670K and bringing the position to 125,000 shares worth $1.58M. The position accounts for 0.21% of the portfolio, ranked #47.

Opaleye Management first reported a position in ENTA in Q4 2016 and has held it in 6 quarters since. The position peaked at $4.68M in Q3 2017. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Opaleye Management held 125,000 shares of Enanta Pharmaceuticals worth $1.58M as of Q1 2026.
  • Opaleye Management bought 50,000 Enanta Pharmaceuticals shares in Q1 2026, an estimated $670K.
  • Enanta Pharmaceuticals made up 0.21% of Opaleye Management's portfolio in Q1 2026, its #47 holding.
  • Opaleye Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and has held it in 6 quarters since.
  • Opaleye Management's Enanta Pharmaceuticals position peaked at $4.68M in Q3 2017.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.